#USA #Clinical Trials #Conshohocken #Suvoda #RTSM

Introduction

In the rapidly evolving landscape of clinical trials, time is a pivotal factor. The commitment to bring new therapies to patients swiftly has prompted innovative solutions, and Suvoda is at the forefront of this change. The company's unveiling of agentic RTSM marks a significant leap in clinical trial technology, with capabilities to cut the startup timeline by as much as 80%. This groundbreaking advancement not only highlights Suvoda's dedication to efficiency but also addresses the urgent needs of sponsors and patients alike.

The Challenge of Clinical Trial Timelines

Traditionally, moving a clinical trial from contract signing to active enrollment can stretch out for months. This delay poses a substantial hurdle in the pursuit of timely patient access to cutting-edge therapies. For sponsors, the lengthy launch periods have become a persistent challenge that requires immediate resolution. In answer to this pressing issue, Suvoda has introduced a solution that leverages advanced AI technology.

The Agentic RTSM Solution

Agentic RTSM represents the latest evolution of Suvoda's Interactive Response Technology (IRT), powered by agentic AI capabilities. This system is designed to expedite clinical trial processes, taking studies from the initial project kickoff to User Acceptance Testing (UAT) in an impressive two weeks. This rapid transition not only accelerates timelines but also enhances the overall experience for both sponsors and trial sites.

Key Outcomes

Suvoda's agentic RTSM is underpinned by a comprehensive AI strategy that delivers three fundamental outcomes:
1. Accelerated Study Builds: By reducing the kickoff to UAT time by up to 80%, the platform enables patients to receive treatments faster than ever before.
2. Enhanced User Experience: The introduction of agentic RTSM provides sponsors and sites with quicker access to trial information, significantly streamlining interactions and reducing administrative burdens.
3. Intelligent Insights: The platform offers clear visibility into trial status and supports smarter decision-making through data analytics and insights.

By deploying multiple AI agents throughout various phases of the study build—ranging from software configuration to testing—Suvoda has innovated a process that minimizes delays and improves efficiency. The agentic RTSM system is backed by the patented Suvoda Platform, using its Virtual Partition architecture and low-code tools, thus allowing for quick adaptations without starting from scratch.

The Vision Behind Agentic RTSM

Jagath Wanninayake, CEO of Suvoda, emphasizes that as clinical trials grow increasingly complex and urgent, technology must evolve to eliminate delays. The focus of agentic RTSM is to alleviate the friction commonly associated with trial startups, enabling sponsors to begin the patient enrollment process at an accelerated pace. This innovation aims to ensure that study teams can dedicate their time to clinical tasks that truly matter, rather than getting bogged down by administrative responsibilities.

In addition to agentic RTSM, Suvoda is actively developing its AI assistant, Sofia, to enhance trial monitoring, alerting processes, and automating necessary actions with built-in safeguards. The future of agentic technology will encompass areas such as electronic Clinical Outcome Assessments (eCOA) and financial solutions, promising the same efficiency and consistency for questionnaire-based research, participant travel, and payment processes.

Conclusion

At the core of Suvoda's advancements is a dedication to all stakeholders in clinical trials, including sponsors testing new treatments, sites conducting the trials, and the patients awaiting the breakthrough therapies. By shortening startup times, Suvoda is not just improving operational metrics; they are actively working to bring life-saving medicines to those in need more swiftly. The introduction of agentic RTSM is merely the beginning of an expansive AI vision where speed, quality, and user experience coexist harmoniously, pushing the boundaries of what is achievable in clinical research. As Suvoda moves forward, the commitment to elevating every moment of the clinical trial process remains unwavering.

About Suvoda

Suvoda is a premier global clinical trial technology enterprise based just outside Philadelphia. It provides innovative, real-time software platforms that empower sponsors and contract research organizations (CROs) to make informed decisions and ensure patient safety throughout trials. Committed to enhancing the trial experience, Suvoda supports over 6,000 trials across 115 countries, consistently exceeding customer satisfaction scores in the technology sector. With ongoing enhancements in technology and services, Suvoda stands prepared to drive the future of clinical trials simply and efficiently.